Privia HealthPRVA
PRVA
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
198% more call options, than puts
Call options by funds: $7.97M | Put options by funds: $2.68M
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
60% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 63
8% more capital invested
Capital invested by funds: $2.18B [Q3] → $2.35B (+$167M) [Q4]
0.13% less ownership
Funds ownership: 100.22% [Q3] → 100.09% (-0.13%) [Q4]
2% less funds holding
Funds holding: 232 [Q3] → 228 (-4) [Q4]
10% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 30
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
9%
upside
Avg. target
$29
29%
upside
High target
$40
75%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Needham Ryan MacDonald 40% 1-year accuracy 34 / 84 met price target | 31%upside $30 | Buy Reiterated | 21 Mar 2025 |
Citizens Capital Markets Constantine Davides 30% 1-year accuracy 10 / 33 met price target | 27%upside $29 | Market Outperform Maintained | 28 Feb 2025 |
Canaccord Genuity Richard Close 41% 1-year accuracy 11 / 27 met price target | 31%upside $30 | Buy Maintained | 28 Feb 2025 |
Piper Sandler Sean Wieland 0% 1-year accuracy 0 / 1 met price target | 75%upside $40 | Overweight Maintained | 28 Feb 2025 |
JMP Securities Constantine Davides 30% 1-year accuracy 10 / 33 met price target | 14%upside $26 | Market Outperform Maintained | 14 Feb 2025 |
Financial journalist opinion
Positive
Invezz
4 weeks ago
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings growth potential.

Positive
Zacks Investment Research
1 month ago
Here's What Key Metrics Tell Us About Privia Health (PRVA) Q4 Earnings
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Neutral
Seeking Alpha
1 month ago
Privia Health Group, Inc. (PRVA) Q4 2024 Earnings Call Transcript
Privia Health Group, Inc. (NASDAQ:PRVA ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Robert Borchert - Senior Vice President-Investor & Corporate Communications Parth Mehrotra - Chief Executive Officer David Mountcastle - Chief Financial Officer Conference Call Participants Sameer Patel - Evercore ISI Andrew Mok - Barclays Josh Raskin - Nephron Research Whit Mayo - Leerink Partners Jailendra Singh - Truist Securities A.J. Rice - UBS Jack Slevin - Jeffries Jeff Garro - Stephens Inc Matthew Gillmor - KeyBanc Richard Close - Canaccord Genuity Matt Shea - Needham Ryan Langston - TD Cowen David Larsen - BTIG Adam Ron - Bank of America Michael Ha - Baird Constantine Davides - Citizens JMP Daniel Grosslight - Citi Jessica Tassan - Piper Sandler Tao Qiu - Macquarie Craig Jones - Stifel Operator Thank you for standing by.

Negative
Zacks Investment Research
1 month ago
Privia Health (PRVA) Lags Q4 Earnings Estimates
Privia Health (PRVA) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.02 per share a year ago.

Neutral
GlobeNewsWire
1 month ago
Privia Health Reports Fourth Quarter and Full-Year 2024 Financial Results
All 2024 Operating and Financial Metrics Above High End of Guidance Ranges Very strong New Provider Signings with Implemented Providers +11.2% from Year-end 2023 Full-year 2024 Net Cash Provided by Operating Activities of $109.3 million, +35.3% from 2023, with De Minimis Capital Expenditures Year-end 2024 Cash Balance of $491.1 million and No Debt 2025 Guidance Reflects Continued Momentum and Profitable Growth Despite Challenging Medicare Advantage and Value-based Environment ARLINGTON, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2024.

Positive
Zacks Investment Research
1 month ago
Seeking Clues to Privia Health (PRVA) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Privia Health (PRVA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Neutral
GlobeNewsWire
2 months ago
Privia Health to Report Fourth Quarter 2024 Results on Thursday, February 27
ARLINGTON, Va., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth quarter and full-year periods ended December 31, 2024 before market open on Thursday, February 27, 2025.

Positive
Zacks Investment Research
2 months ago
DH or PRVA: Which Is the Better Value Stock Right Now?
Investors interested in Medical Info Systems stocks are likely familiar with Definitive Healthcare Corp. (DH) and Privia Health (PRVA). But which of these two companies is the best option for those looking for undervalued stocks?

Positive
Zacks Investment Research
3 months ago
DH vs. PRVA: Which Stock Is the Better Value Option?
Investors with an interest in Medical Info Systems stocks have likely encountered both Definitive Healthcare Corp. (DH) and Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?

Positive
Zacks Investment Research
3 months ago
DH vs. PRVA: Which Stock Should Value Investors Buy Now?
Investors interested in Medical Info Systems stocks are likely familiar with Definitive Healthcare Corp. (DH) and Privia Health (PRVA). But which of these two stocks offers value investors a better bang for their buck right now?

Charts implemented using Lightweight Charts™